Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Sialorrhea
Interventions
DRUG

Incobotulinum Toxin A

Twenty units (0.2 ml) of incobotulinum toxin A were injected into each parotid gland and 30 units (0.3 ml) to each submandibular gland for a total dose of 100 units using anatomical landmarks

DRUG

Placebo

Sterile, preservative free 0.9% saline, 1 ml, was used as placebo, and injected into the parotid (0.2 ml each) and submandibular (0.3ml each) glands .

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
lead

Beth Israel Deaconess Medical Center

OTHER

NCT01653132 - Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism | Biotech Hunter | Biotech Hunter